SOUTH SAN FRANCISCO, Calif., May 1, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, and Brian Wong, Vice President, Research and Head of Immuno-Oncology, will present at the Credit Suisse Antibody Day on Wednesday, May 6 at 3:00 PM Eastern Daylight Time. The conference will take place at Credit Suisse's offices at One Madison Avenue, New York City.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://cc.talkpoint.com/cred001/050615a_ae/?entity=10_3QKRJ5G. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Amy Kendall, Corporate Communications 415-365-5776 firstname.lastname@example.org
Source:Five Prime Therapeutics, Inc.